What Does Science Say About Omega-3 Fatty Acids and Specific conditions ?

Minami Nutrition is about proof NOT promises. Our product range are produced as a result of our committment to research that examines the effect of Omega-3 fats on a variety of medical areas, including Dyslexia, Dyspraxia, Attention Deficit Hyperactivity Disorder (AD/HD) as well as Heart Disease and Wellness issues.

Clinical studies show that Omega-3 fatty acids are well tolerated by children and adults. The general consensus is that 1 g of EPA + DHA per day is sufficient to maintain optimum performance of the cardiovascular system in most people.*

Ongoing scientific research is revealing more about the enormous potential for Omega-3 fatty acids to positively impact on a range of health outcomes.*

Heart and Cardiovascular Disease*:
Prevention = 1 g EPA + DHA/day (1,2)
With high blood triglycerides = 2 to 4 g EPA + DHA/day (6-9-10)

Attention Deficit Hyperactivity Disorder (AD/HD), Dyslexia, Dyspraxia*:
0.5 to 1 g EPA/day (4-16)

Depression*
1g (no DHA) day (3)

Bipolar Disorder* 1- 2g (no DHA) day as supplementary treatment with standard therapy (11-13)

Schizophrenia*:
2 g EPA/day as supplementary treatment with standard therapy (14)

Mood Disorder (aggression)*:
1 to 2 g EPA/day (15)

Pregnancy and Breast Feeding*:
220 to 800 mg EPA/day and 300 mg to 1 g DHA/day (17-19-20)

Brain and Visual Development*:
20-40 mg DHA/2.2 lb. body weight/day (21)

Preventive measures

- It is advisable not to take Omega-3 supplements if you are allergic to fish or gelatin It is advisable to tell your physician that you are taking Omega-3 supplements if you are about to have surgery or take anticoagulants

REFERENCES

1. AHA: American Heart Association
2. ESC: European Society of Cardiology
3. Comparison of therapeutic effects of Omega-3 fatty acid PLUSEPA® eicosapentaenoic
acid and fluoxetine, separately and in combination, in major depressive disorder. Aust N Z J Psychiatry 2008; 42(3):192-8.). Jazayeri S, Tehrani-Doost M, Keshavarz SA et al.
4. Placebo controlled, randomised, double-blind, multicentre study of PLUSEPA® (a PUFA, Polyunsaturated Fatty Acids, supplement) as treatment for ADHD (combined type) with co-morbidity in Swedish children ages 7-12. accepted for publication in Acta Paedriatica. Gustafsson PA, Birberg-Thornberg U, Duchén K, Strandvik B, Karlsson T.
5. Effects of Eicosapentaenoic Acid (PLUSEPA®) and Vitamin E on the Plasma Levels of Antioxidant Vitamins and Inflammatory Markers, and on Erythrocyte Antioxidant Enzyme Activities, in Male Basketball Players Reza Ghiasvand, Mahmoud Djalali, Seyed Abolghassem Djazayery, Seyed Ali Keshavarz, and Mostafa Hosseini.
6.. Clinical importance of adherence to treatment with eicosapentaenoic acid by patients with hypercholesterolemia. Cl. Journal 2010 Feb 25;74(3):510-7. Epub 2010 Feb 9Origasa H, Yokoyama M, Matsuzaki M, Saito Y, Matsuzawa Y; JELIS Investigators
7. Omega-3 fatty acids (MorEPA fish-oil) and depression-related cognition in healthy volunteers.. J Psychopharmacol. 2009 Sep;23(7):831-40. Epub 2008 Jun 26. Antypa N, Van der Does AJ, Smelt AH, Rogers RD
8. No effect of n-3 long-chain polyunsaturated fatty acid (EPA and DHA) supplementation on depressed mood and cognitive function: a randomised controlled trial. Br J Nutr 2008 Feb; 99(2):421-31 (Epub 2007 Oct 24). Rogers PJ, Appleton KM, Kessler D, Peters TJ, Gunnell D, Hayward RC, Heatherley SV, Christian LM, McNaughton SA, Ness AR
9. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999; 354(9177):447-55.
10. F; GISSI-Prevenzione Investigators. Antiarrhythmic mechanisms of n-3 PUFA and the results of the GISSI-Prevenzione trial. J Membr Biol 2005; 206(2):117-28. Marchioli R, Levantesi G, Macchia A, Maggioni AP, Marfisi RM, Silletta MG, Tavazzi L, Tognoni G, Valagussa
11. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry 2002; 59(10):913-9. Peet M, Horrobin DF.
12. Omega-3 eicosapentaenoic acid in bipolar depression : Report of a small open-label study. J Clin Psych 2005; 66(6):726-9. Osher Y, Bersudsky Y, Belmaker RH.
13. Omega-3 fatty acids decreased irritability of patients with bipolar disorder in an add-on, open label study. Nutr J 2005 Feb 9;4(1):6. Sagduyu K, Dokucu ME, Eddy BA, Craigen G, Baldassano CF, Yildiz A.
14. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr Res. 2001 Apr 30;49(3):243-51. Peet M, Brind J, Ramchand CN, Shah S, Vankar GK.
15. Omega-3 Fatty acid treatment of women with borderline personality disorder: a double-blind, placebocontrolled pilot study. Am J Psychiatry 2003; 160(1):167-9. Zanarini MC, Frankenburg FR.
16. Clinical trials of fatty acid treatment in ADHD, dyslexia, dyspraxia and the autistic spectrum. Prostaglandins Leukot Essent Fatty Acids 2004; 70(4):383-90. Richardson AJ.
17. The importance of the ratio of Omega-6/Omega-3 essential fatty acids. Biomed Pharmacother 2002; 56(8):365-79. Simopoulos AP.
18. Polyunsaturated fatty acids and risk of preterm delivery. Eur Rev Med Pharmacol Sci 2005; 9(1):41-8. Facchinetti F, Fazzio M, Venturini P.
19. Maternal supplementation with very-long-chain n-3 fatty acids during pregnancy and lactation augments children's IQ at 4. Helland IB, Smith L, Saarem K, Saugstad OD, Drevon CA.
20.Maternal-fetal in vivo transfer of [13C]docosahexaenoic and other fatty acids across the human placenta 12 h after maternal oral intake Gil-Sánchez A, Larqué E, Demmelmair H, Acien MI, Faber FL, Parrilla JJ, Koletzko BAm J Clin Nutr. 2010 May 5
21. WHO: World Health Organisation. Report of a joint expert FAO/WHO consultation, 1994.
22. EFSA to represent typical recommended daily intakes for adults 2010